Whole genome sequencing in adults with clinical hallmarks of hypophosphatasia negative for ALPL variants.


Journal

Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234

Informations de publication

Date de publication:
14 Sep 2024
Historique:
received: 19 04 2024
accepted: 03 09 2024
medline: 14 9 2024
pubmed: 14 9 2024
entrez: 14 9 2024
Statut: epublish

Résumé

Hypophosphatasia (HPP) is a rare disease caused by deficient activity of tissue-nonspecific alkaline phosphatase (ALP), encoded by the ALPL gene. The primary objective was to explore novel ALPL variants by whole genome sequencing (WGS) in patients with HPP who previously tested negative by standard methods for ALPL variants. The secondary objective was to search for genes beyond ALPL that may reduce ALP activity or contribute to HPP symptoms. WGS was performed in 16 patients clinically diagnosed with HPP who had ALP activity below the normal range and tested negative for ALPL variants. Genetic variants in ALPL and genes possibly associated with low ALP activity or phenotypic overlap with HPP were assessed. All 16 patients had ALP activity below the normal range. WGS did not identify any novel disease-causing ALPL variants. Positive findings for other gene variants were identified in 4 patients: 1 patient presented with variants in COL1A1, NLRP12, and SCN9A, coding for collagen, type, I alpha-1 chain, nod-like receptor pyrin domain containing 12, and sodium voltage-gated channel alpha subunit 9, respectively; 1 presented with a heterozygous, likely pathogenic variant in P3H1 coding for prolyl 3 hydroxylase 1; 1 presented with a heterozygous pathogenic variant in SGCE, coding for sarcoglycan epsilon; and 1 presented with a heterozygous variant of uncertain significance in VDR, encoding vitamin D receptor. Genomic analysis did not identify novel ALPL variants or a pattern of disease-causing variants in genes other than ALPL to explain the HPP phenotype in these patients. Clinicaltrials.gov identifier: NCT04925804.

Sections du résumé

BACKGROUND BACKGROUND
Hypophosphatasia (HPP) is a rare disease caused by deficient activity of tissue-nonspecific alkaline phosphatase (ALP), encoded by the ALPL gene. The primary objective was to explore novel ALPL variants by whole genome sequencing (WGS) in patients with HPP who previously tested negative by standard methods for ALPL variants. The secondary objective was to search for genes beyond ALPL that may reduce ALP activity or contribute to HPP symptoms.
METHODS AND RESULTS RESULTS
WGS was performed in 16 patients clinically diagnosed with HPP who had ALP activity below the normal range and tested negative for ALPL variants. Genetic variants in ALPL and genes possibly associated with low ALP activity or phenotypic overlap with HPP were assessed. All 16 patients had ALP activity below the normal range. WGS did not identify any novel disease-causing ALPL variants. Positive findings for other gene variants were identified in 4 patients: 1 patient presented with variants in COL1A1, NLRP12, and SCN9A, coding for collagen, type, I alpha-1 chain, nod-like receptor pyrin domain containing 12, and sodium voltage-gated channel alpha subunit 9, respectively; 1 presented with a heterozygous, likely pathogenic variant in P3H1 coding for prolyl 3 hydroxylase 1; 1 presented with a heterozygous pathogenic variant in SGCE, coding for sarcoglycan epsilon; and 1 presented with a heterozygous variant of uncertain significance in VDR, encoding vitamin D receptor.
CONCLUSION CONCLUSIONS
Genomic analysis did not identify novel ALPL variants or a pattern of disease-causing variants in genes other than ALPL to explain the HPP phenotype in these patients.
REGISTRATION BACKGROUND
Clinicaltrials.gov identifier: NCT04925804.

Identifiants

pubmed: 39276275
doi: 10.1007/s11033-024-09906-7
pii: 10.1007/s11033-024-09906-7
doi:

Substances chimiques

ALPL protein, human EC 3.1.3.1
Alkaline Phosphatase EC 3.1.3.1

Banques de données

ClinicalTrials.gov
['NCT04925804']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

984

Informations de copyright

© 2024. The Author(s).

Références

Khan A, Brandi ML, Rush ET, Ali DS, Al-Alwani H, Almonaei K, Alsarraf F, Bacrot S, Dahir K, Dandurand K, Deal C, Ferrari SL, Giusti F, Guyatt G, Hatcher E, Ing SW, Javaid MK, Khan S, Kocijan R, Linglart A, M’Hiri I, Marini F, Nunes ME, Rockman-Greenberg C, Roux C, Seefried L, Simmons JH, Starling SR, Ward LM, Yao L, Brignardello-Petersen R, Lewiecki EM (2024) Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults. Osteoporos Int 35:431–438. https://doi.org/10.1007/s00198-023-06844-1
doi: 10.1007/s00198-023-06844-1 pubmed: 37982857
Michigami T, Ohata Y, Fujiwara M, Mochizuki H, Adachi M, Kitaoka T, Kubota T, Sawai H, Namba N, Hasegawa K, Fujiwara I, Ozono K (2020) Clinical practice guidelines for hypophosphatasia. Clin Pediatr Endocrinol 29:9–24. https://doi.org/10.1297/cpe.29.9
doi: 10.1297/cpe.29.9 pubmed: 32029969 pmcid: 6958520
Kishnani PS, Rush ET, Arundel P, Bishop N, Dahir K, Fraser W, Harmatz P, Linglart A, Munns CF, Nunes ME, Saal HM, Seefried L, Ozono K (2017) Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. Mol Genet Metab 122:4–17. https://doi.org/10.1016/j.ymgme.2017.07.010
doi: 10.1016/j.ymgme.2017.07.010 pubmed: 28888853
Mornet E, Hofmann C, Bloch-Zupan A, Girschick H, Le Merrer M (2014) Clinical utility gene card for: hypophosphatasia – update 2013. Eur J Hum Genet 22. https://doi.org/10.1038/ejhg.2013.177
JKU Faculty of Medicine (2023) The ALPL gene variant database [OMIM *171760]. https://alplmutationdatabase.jku.at/ . Accessed August 16, 2024
De Sousa SM, Hardy TS, Scott HS, Torpy DJ (2018) Genetic testing in endocrinology. Clin Biochem Rev 39:17–28
pubmed: 30072819 pmcid: 6069737
Beck NM, Sagaser KG, Lawson CS, Hertenstein C, Jachens A, Forster KR, Miller KA, Jelin AC, Blakemore KJ, Hoover-Fong J (2023) Not just a carrier: clinical presentation and management of patients with heterozygous disease-causing alkaline phosphatase (ALPL) variants identified through expanded carrier screening. Mol Genet Genomic Med 11:e2056. https://doi.org/10.1002/mgg3.2056
doi: 10.1002/mgg3.2056 pubmed: 36444396
Taillandier A, Domingues C, De Cazanove C, Porquet-Bordes V, Monnot S, Kiffer-Moreira T, Rothenbuhler A, Guggenbuhl P, Cormier C, Baujat G, Debiais F, Capri Y, Cohen-Solal M, Parent P, Chiesa J, Dieux A, Petit F, Roume J, Isnard M, Cormier-Daire V, Linglart A, Millan JL, Salles JP, Muti C, Simon-Bouy B, Mornet E (2015) Molecular diagnosis of hypophosphatasia and differential diagnosis by targeted next generation sequencing. Mol Genet Metab 116:215–220. https://doi.org/10.1016/j.ymgme.2015.09.010
doi: 10.1016/j.ymgme.2015.09.010 pubmed: 26432670 pmcid: 5257278
Yuan X, Waterworth D, Perry JR, Lim N, Song K, Chambers JC, Zhang W, Vollenweider P, Stirnadel H, Johnson T, Bergmann S, Beckmann ND, Li Y, Ferrucci L, Melzer D, Hernandez D, Singleton A, Scott J, Elliott P, Waeber G, Cardon L, Frayling TM, Kooner JS, Mooser V (2008) Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 83:520–528. https://doi.org/10.1016/j.ajhg.2008.09.012
doi: 10.1016/j.ajhg.2008.09.012 pubmed: 18940312 pmcid: 2561937
Stenson PD, Mort M, Ball EV, Shaw K, Phillips A, Cooper DN (2014) The human gene mutation database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet 133:1–9. https://doi.org/10.1007/s00439-013-1358-4
doi: 10.1007/s00439-013-1358-4 pubmed: 24077912
Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Hoover J, Jang W, Katz K, Ovetsky M, Riley G, Sethi A, Tully R, Villamarin-Salomon R, Rubinstein W, Maglott DR (2016) ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res 44:D862–868. https://doi.org/10.1093/nar/gkv1222
doi: 10.1093/nar/gkv1222 pubmed: 26582918
Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O’Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, Tukiainen T, Birnbaum DP, Kosmicki JA, Duncan LE, Estrada K, Zhao F, Zou J, Pierce-Hoffman E, Berghout J, Cooper DN, Deflaux N, DePristo M, Do R, Flannick J, Fromer M, Gauthier L, Goldstein J, Gupta N, Howrigan D, Kiezun A, Kurki MI, Moonshine AL, Natarajan P, Orozco L, Peloso GM, Poplin R, Rivas MA, Ruano-Rubio V, Rose SA, Ruderfer DM, Shakir K, Stenson PD, Stevens C, Thomas BP, Tiao G, Tusie-Luna MT, Weisburd B, Won HH, Yu D, Altshuler DM, Ardissino D, Boehnke M, Danesh J, Donnelly S, Elosua R, Florez JC, Gabriel SB, Getz G, Glatt SJ, Hultman CM, Kathiresan S, Laakso M, McCarroll S, McCarthy MI, McGovern D, McPherson R, Neale BM, Palotie A, Purcell SM, Saleheen D, Scharf JM, Sklar P, Sullivan PF, Tuomilehto J, Tsuang MT, Watkins HC, Wilson JG, Daly MJ, MacArthur DG (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature 536:285–291. https://doi.org/10.1038/nature19057
doi: 10.1038/nature19057 pubmed: 27535533 pmcid: 5018207
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405–424. https://doi.org/10.1038/gim.2015.30
doi: 10.1038/gim.2015.30 pubmed: 25741868 pmcid: 4544753
Seefried L, Kishnani PS, Moseley S, Denker AE, Watsky E, Whyte MP, Dahir KM (2021) Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia. Bone 142:115664. https://doi.org/10.1016/j.bone.2020.115664
doi: 10.1016/j.bone.2020.115664 pubmed: 32987199
Mrosk J, Bhavani GS, Shah H, Hecht J, Krüger U, Shukla A, Kornak U, Girisha KM (2018) Diagnostic strategies and genotype-phenotype correlation in a large Indian cohort of osteogenesis imperfecta. Bone 110:368–377. https://doi.org/10.1016/j.bone.2018.02.029
doi: 10.1016/j.bone.2018.02.029 pubmed: 29499418
Kishnani PS, Martos-Moreno GÁ, Linglart A, Petryk A, Messali A, Fang S, Rockman-Greenberg C, Ozono K, Högler W, Seefried L, Dahir KM (2024) Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry [abstract OC2; oral presentation]. Orphanet J Rare Dis 19:109
doi: 10.1186/s13023-024-03048-6 pubmed: 38459585 pmcid: 10921796
Rauf MA, Kotecha J, Moss K (2023) Reducing diagnostic delay in hypophosphatasia: a case series of 14 patients presenting to general rheumatology. Osteoporos Int 34:1647–1652. https://doi.org/10.1007/s00198-023-06749-z
doi: 10.1007/s00198-023-06749-z pubmed: 37118032 pmcid: 10427523
Maioli M, Gnoli M, Boarini M, Tremosini M, Zambrano A, Pedrini E, Mordenti M, Corsini S, D’Eufemia P, Versacci P, Celli M, Sangiorgi L (2019) Genotype-phenotype correlation study in 364 osteogenesis imperfecta Italian patients. Eur J Hum Genet 27:1090–1100. https://doi.org/10.1038/s41431-019-0373-x
doi: 10.1038/s41431-019-0373-x pubmed: 30886339 pmcid: 6777444
Sam JE, Dharmalingam M (2017) Osteogenesis Imperfecta. Indian J Endocrinol Metab 21:903–908. https://doi.org/10.4103/ijem.IJEM_220_17
doi: 10.4103/ijem.IJEM_220_17 pubmed: 29285457 pmcid: 5729682
Reimann F, Cox JJ, Belfer I, Diatchenko L, Zaykin DV, McHale DP, Drenth JP, Dai F, Wheeler J, Sanders F, Wood L, Wu TX, Karppinen J, Nikolajsen L, Männikkö M, Max MB, Kiselycznyk C, Poddar M, Te Morsche RH, Smith S, Gibson D, Kelempisioti A, Maixner W, Gribble FM, Woods CG (2010) Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc Natl Acad Sci U S A 107:5148–5153. https://doi.org/10.1073/pnas.0913181107
doi: 10.1073/pnas.0913181107 pubmed: 20212137 pmcid: 2841869
Del Porto F, Cifani N, Proietta M, Verrecchia E, Di Rosa R, Manna R, Chiurazzi P (2020) NLRP12 gene mutations and auto-inflammatory diseases: ever-changing evidence. Rheumatology (Oxford) 59:3129–3136. https://doi.org/10.1093/rheumatology/keaa304
Raymond D, Saunders-Pullman R, Ozelius L (2020) Sgce myoclonus-dystonia. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A (eds) Genereviews. Seattle, WA, University of Washington, Seattle
Carlberg C (2022) Vitamin D and its target genes. Nutrients 14. https://doi.org/10.3390/nu14071354
Levine MA (2020) Diagnosis and management of vitamin D dependent rickets. Front Pediatr 8:315. https://doi.org/10.3389/fped.2020.00315
doi: 10.3389/fped.2020.00315 pubmed: 32596195 pmcid: 7303887
Unger S, Mornet E, Mundlos S, Blaser S, Cole DE (2002) Severe cleidocranial dysplasia can mimic hypophosphatasia. Eur J Pediatr 161:623–626. https://doi.org/10.1007/s00431-002-0978-9
doi: 10.1007/s00431-002-0978-9 pubmed: 12424591

Auteurs

Lothar Seefried (L)

Clinical Trial Unit, Orthopedic Department, University of Würzburg, Brettreichtstr. 11, 97074, Würzburg, Bavaria, Germany. l-seefried.klh@uni-wuerzburg.de.

Anna Petryk (A)

Alexion, AstraZeneca Rare Disease, Boston, MA, USA.

Guillermo Del Angel (G)

Alexion, AstraZeneca Rare Disease, Boston, MA, USA.

Felix Reder (F)

Centogene GmbH, Rostock, Germany.

Peter Bauer (P)

Centogene GmbH, Rostock, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH